Skip to main content
TipRanks
Go Ultimate75% OFF

Latigo Biotherapeutics, Inc. (LTGO) Financial Statements

39 Followers

Latigo Biotherapeutics, Inc. Financial Overview

Latigo Biotherapeutics, Inc.'s market cap is currently $857.25M. The company's EPS TTM is $-1.50; its P/E ratio is -8.74; Latigo Biotherapeutics, Inc. has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.

Financial overview
Dec 25
Income Statement
Total Revenue$ 0.00
Gross Profit$ 0.00
Operating Income$ -110.39M
EBITDA$ -110.14M
Net Income$ -109.17M
Balance Sheet
Cash & Short-Term Investments$ 69.44M
Total Assets$ 75.52M
Total Debt$ 690.00K
Net Debt$ -68.75M
Total Liabilities$ 307.19M
Stockholders' Equity$ -231.67M
Cash Flow
Free Cash Flow$ -97.69M
Operating Cash Flow$ -97.56M
Investing Cash Flow$ -136.00K
Financing Cash Flow$ 149.50M

Currency in USD

Latigo Biotherapeutics, Inc. Earnings and Revenue History

-120M-80M-40M00 %0.4 %0.8 %1.2 %EarningsProfit Margin2025RevenueEarningsProfit Margin

Latigo Biotherapeutics, Inc. Liabilities to Assets

0120M240M360M405 %406 %407 %408 %LiabilitiesLiabilities to Assets2025AssetsLiabilitiesLiabilities to Assets

Latigo Biotherapeutics, Inc. Cash Flow

-150M-100M-50M050M100M150M200M2025OperatingInvestingFinancing

Latigo Biotherapeutics, Inc. Forecast EPS vs Actual EPS

-40-30-20-10010Q2 26Q3 26EPS EstimateBeatMiss